Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $10.25.

Several research analysts have issued reports on SGMO shares. Zacks Investment Research cut Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 10th. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BidaskClub cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $17.00 price objective on shares of Sangamo Therapeutics in a research report on Thursday, June 22nd. Finally, Piper Jaffray Companies set a $8.00 price objective on Sangamo Therapeutics and gave the company a “hold” rating in a research report on Thursday, August 10th.

In other news, VP Curt A. Herberts III sold 11,474 shares of Sangamo Therapeutics stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $10.44, for a total transaction of $119,788.56. Following the transaction, the vice president now directly owns 23,991 shares of the company’s stock, valued at approximately $250,466.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $15.00, for a total value of $225,000.00. Following the transaction, the vice president now directly owns 15,833 shares in the company, valued at $237,495. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,474 shares of company stock worth $494,789. Insiders own 8.10% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of SGMO. Highbridge Capital Management LLC bought a new position in Sangamo Therapeutics during the first quarter worth $496,000. Gilder Gagnon Howe & Co. LLC acquired a new position in Sangamo Therapeutics during the first quarter worth approximately $154,000. Wells Fargo & Company MN boosted its position in Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 34,128 shares in the last quarter. United Services Automobile Association acquired a new position in Sangamo Therapeutics during the first quarter worth approximately $1,394,000. Finally, Schwab Charles Investment Management Inc. boosted its position in Sangamo Therapeutics by 5.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 265,735 shares of the biopharmaceutical company’s stock worth $1,382,000 after buying an additional 14,022 shares in the last quarter. 63.43% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics (SGMO) traded up 6.74% during midday trading on Friday, reaching $14.25. 5,064,289 shares of the company’s stock traded hands. The stock’s market cap is $1.19 billion. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $15.05. The stock’s 50 day moving average price is $10.04 and its 200-day moving average price is $7.00.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.06. The business had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The business’s revenue for the quarter was up 124.3% on a year-over-year basis. During the same period last year, the firm posted ($0.38) earnings per share. Equities analysts predict that Sangamo Therapeutics will post ($0.82) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Sangamo Therapeutics, Inc. (SGMO) Receives Consensus Recommendation of “Hold” from Brokerages” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/02/sangamo-therapeutics-inc-sgmo-receives-consensus-recommendation-of-hold-from-brokerages.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Stock Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related stocks with our FREE daily email newsletter.